| Aug 9 |
NeurAxis Reports Second Quarter 2024 Financial Results
|
| Aug 5 |
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024
|
| Jun 7 |
NeurAxis Submits Application to FDA to Expand IB-Stim Label
|
| Jun 7 |
NeurAxis announces new submission to FDA for expansion of its IB-Stim label
|
| Jun 7 |
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure
|
| May 22 |
NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript
|
| May 22 |
NeurAxis Reports First Quarter 2024 Financial Results
|
| May 22 |
NeurAxis GAAP EPS of -$0.32, revenue of $0.65M
|
| May 21 |
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
|
| May 16 |
NeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida
|
